Loading...

Ultra-LEAF™ Purified anti-mouse CD16/32 Antibody

Pricing & Availability
Clone
93 (See other available formats)
Regulatory Status
RUO
Other Names
Fcγ R III/II, Ly-17
Isotype
Rat IgG2a, λ
Ave. Rating
Submit a Review
Product Citations
publications
93_LEAF_051906
C57BL/6 mouse splenocytes stained with Ultra-LEAF™ purified CD16/32 (clone 93), followed by anti-rat IgG FITC.
  • 93_LEAF_051906
    C57BL/6 mouse splenocytes stained with Ultra-LEAF™ purified CD16/32 (clone 93), followed by anti-rat IgG FITC.
Compare all formats
Cat # Size Price Quantity Check Availability Save
101340 25 mg 1408 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
101342 100 mg 3383 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
101341 50 mg 2354 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
101329 100 µg 110 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
101330 1 mg 164 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
101339 5 mg 539 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote

Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.

Description

CD16 is low affinity IgG Fc receptor III (FcR III) and CD32 is FcR II. CD16/CD32 are expressed on B cells, monocytes/macrophages, NK cells, granulocytes, mast cells, and dendritic cells. The Fc receptors bind antibody-antigen immune complexes and mediate adaptive immune responses.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Sorted pre-B cells
Formulation
0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level
Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation
The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration
The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application

FC - Quality tested
IP, Block - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µl volume or 100 µl of whole blood.  It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone 93 can be used for blocking of CD16/CD32 interactions with the Fc domain of immunoglobulins, but is not the same clone as 2.4G2.

The 93 mAb is specific to the common epitope of CD16/CD32. Additional reported applications (for the relevant formats) include: immunoprecipitation1 and blocking of Fc-mediated reactions in functional studies2,4,23. It is useful for blocking non-specific binding of immunoglobulin to Fc receptors. For blocking of Fc receptors in flow cytometric analysis, pre-incubate the cells with purified anti-CD16/CD32 antibody (=1.0 µg per 106 cells in 100 µL volume) for 5-10 minutes on ice prior to immunostaining. For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 101330) (Endotoxin <0.01 EU/µg, Azide-Free, 0.2 µm filtered).

Application References

(PubMed link indicates BioLegend citation)
  1. Personal communication (IP)
  2. Oliver AM, et al. 1999. Hybridoma 18:113. (Block)
  3. Brummel R and Lenert P. 2005. J. Immunol. 174:2429.
  4. Terrazas LI, et al. 2005. Int. J. Parasitol. 35:1349. (Block)
  5. Clements JL, et al. 2006. J. Immunol. 177:905.
  6. Mohamed W, et al. 2010. Infect Immun. 78:3306. PubMed
  7. Ouchi T, et al. 2011. J. Exp Med. 208:2607. PubMed
  8. Kmieciak M, et al. 2011. J. Vis. Exp. 47:2381. PubMed
  9. Yamazaki S, et al. 2012. PLoS One. 7:e51665. PubMed
  10. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  11. Azuma M, et al. 2012. Oncoimmunology. 1:581. PubMed
  12. Koon HW, et al. 2013. J. Vis. Exp. 68:4208. PubMed
  13. Hegde VL, et al. 2013. J Biol Chem. 288:36810. PubMed
  14. Huang J, et al. 2013. J. Immunol Methods. 387:254. PubMed
  15. Dutow P, et al. 2014. J Infect Dis. PubMed
  16. Fan Y, et al. 2014. J Exp Med. 211:313. PubMed
  17. Huang HN, et al. 2014. Antimicrob Agents Chemother. 58:1538. PubMed
  18. Takei S, et al. 2014. Vaccine. 32:3066. PubMed
  19. Richardson ML, et al. 2014. PLoS Negl Trop Dis. 8:2825. PubMed
  20. Cekanaviciute E, et al. 2014. J Immunol. 193:139. PubMed
  21. Kimura T, et al. 2014. Int Immunol. 26:697. PubMed
  22. Everad A, et al. 2014. Nat Commun. 5:5648. PubMed
  23. Cenci E, et al. 2006. J. Leuko. Biol. 79(1):40-5. (Block)
Product Citations
  1. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  2. van Os BW, et al. 2023. Eur Heart J Open. 3:oead013. PubMed
  3. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  4. Matsudaira T, et al. 2023. Commun Biol. 6:665. PubMed
  5. Liang Y, et al. 2021. Cell Death Differ. 28:2728. PubMed
  6. Miranda K, et al. 2022. iScience. 25:104994. PubMed
  7. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  8. Yang L, et al. 2023. Sci Rep. 13:1827. PubMed
  9. Nair N, et al. 2020. Curr Protoc Microbiol. 59:e127. PubMed
  10. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  11. Petursdottir D, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01699. PubMed
  12. Xie Y, et al. 2020. Journal of Neurochemistry. 152(3):368-380.. PubMed
  13. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  14. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  15. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  16. Guérin MV, et al. 2019. Nat Commun. 10:4131. PubMed
  17. Guo P, et al. 2021. J Immunol. 207:408. PubMed
  18. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  19. Arensman MD, et al. 2020. Oncoimmunology. 9:1800162. PubMed
  20. Le TM et al. 2018. Journal of neurochemistry. 145(2):139-153 . PubMed
  21. Fox A, et al. 2020. Current Protocols in Cytometry. 93(1):e74. PubMed
  22. Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed
  23. Tong Y, et al. 2018. EBioMedicine. 39:132. PubMed
  24. Trindade BC, et al. 2021. Immunity. 54:2273. PubMed
  25. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
RRID
AB_2561482 (BioLegend Cat. No. 101340)
AB_2561482 (BioLegend Cat. No. 101342)
AB_2561482 (BioLegend Cat. No. 101341)
AB_2561482 (BioLegend Cat. No. 101329)
AB_2561482 (BioLegend Cat. No. 101330)
AB_2561482 (BioLegend Cat. No. 101339)

Antigen Details

Structure
Ig superfamily, 40-60 kD
Distribution

B cells, monocyte/macrophages, NK cells, neutrophils, mast cells, dendritic cells

Function
Low affinity receptors for IgG
Ligand/Receptor
IgG
Cell Type
B cells, Dendritic cells, Macrophages, Mast cells, Monocytes, Neutrophils, NK cells
Biology Area
Immunology, Innate Immunity
Molecular Family
CD Molecules, Fc Receptors
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Unkeless JC. 1989. J. Clin. Invest. 83:355.
3. Qiu WQ, et al. 1990. Science 248:732.

Gene ID
14130 View all products for this Gene ID 14131 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD16/32
Specificity Alt (DOES NOT SHOW ON TDS):
CD16/32
App Abbreviation (DOES NOT SHOW ON TDS):
FC,IP,Block
UniProt
View information about CD16/32 on UniProt.org

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Go To Top Version: 4    Revision Date: 06.06.2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account